Several studies demonstrate that the treatment with lamivudine alone, or in combination with interleukin-12 (IL-12), result in the restoration of the HBV-specific CD4 + and CD8 + immune response in chronic HBV-infected individuals. However, the therapeutic effect was not sustained in those patients [55] [56] [57] .